PROPULSID
LOE ApproachingNDAORALTABLET
Approved
Jul 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROPULSID (cisapride) is an oral small-molecule prokinetic agent approved by the FDA in 1993. The drug enhances gastric motility and accelerates gastric emptying, making it useful for symptomatic gastroesophageal reflux disease (GERD) and other upper GI motility disorders. It works by blocking dopamine receptors and enhancing acetylcholine effects on smooth muscle.
LOE Approaching
Nearing loss of exclusivity with minimal competitive pressure, suggesting a mature, stabilized team focused on lifecycle extension or orderly transition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PROPULSID offers stability in a mature product environment but limited growth trajectory. Professionals should view this role as a platform for execution excellence, stakeholder management, and transition planning as LOE approaches.
Brand ManagerMedical Science Liaison
Worked on PROPULSID at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.